載入中
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
前收盤價
US$9.31
−US$0.57 · -5.77%
盤中時間採用ET。市場資料可能有所延遲。
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
日內區間
目前US$9.31
52週區間
目前US$9.31
盤中時間採用ET。市場資料可能有所延遲。
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
日內區間
目前US$9.31
52週區間
目前US$9.31
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4847.1萬 USD | 1.15億 USD | — | — | — |
| 銷貨成本 | 100.2萬 USD | — | — | — | — |
| 毛利 | 4746.9萬 USD | 1.15億 USD | — | — | — |
| 研究與開發 | 1.74億 USD | 1.38億 USD | 1.35億 USD | 1.71億 USD | 1.7億 USD |
| 銷售、一般及管理費用 | 3763.1萬 USD | 3613.3萬 USD | 3845.5萬 USD | 4760.9萬 USD | 4578.2萬 USD |
| 營業費用 | 2.11億 USD | 1.75億 USD | 1.84億 USD | 2.19億 USD | 2.16億 USD |
| 利息收入 | 197萬 USD | 177.9萬 USD | 199.7萬 USD | 158.3萬 USD | 76.1萬 USD |
| 利息支出 | 1098.9萬 USD | 1151.7萬 USD | 1351.1萬 USD | 1388萬 USD | 1944萬 USD |
| 折舊和攤銷 | 100.2萬 USD | 415.1萬 USD | 438.5萬 USD | 442.9萬 USD | 516.7萬 USD |
| 營業利益 | −1.63億 USD | −5991.9萬 USD | −1.84億 USD | −2.19億 USD | −2.16億 USD |
| 淨利 | −1.7億 USD | −5652.8萬 USD | −1.8億 USD | −2.29億 USD | −2.34億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI117.49萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Biotechnology ETFIBB42.95萬0.00%108.2億 USD0.44%US$206.49+3.00%
Vanguard Extended Market ETFVXF38.14萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Health Care ETFVHT22.42萬0.00%220億 USD0.09%US$319.01+1.64%
Invesco RAFI US 1500 Small-Mid ETFPRFZ11.7萬0.00%26.7億 USD0.36%US$53.16+0.64%
Eventide Small Cap ETFESSC2.97萬0.09%3500萬 USD0.49%US$28.76+0.45%
Invesco Nasdaq Biotechnology ETFIBBQ4059.160.00%1.12億 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB2187.850.00%9320.36萬 USD1.19%US$110.98+5.68%Vanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEventide Small Cap ETFESSCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
